Sort
51,570 grants matching “autoimmune disease”
Innate Functions of Dendritic Cells in Autoreactivity
$1,550,959Rockefeller University · P01 · FY2002 · AI
Oklahoma Sjogren's Syndrome Center of Research Translation
$1,550,076Kathy L. Moser · Oklahoma Medical Research Foundation · P50 · FY2012 · AR
Immune Cells and Secretory Pathways Leading to Human Systemic Autoimmunity
$1,550,000Maria Virginia Pascual · Weill Medical Coll Of Cornell Univ · U19 · FY2021 · AI
Administrative Core
$1,550,000Maria Virginia Pascual · Weill Medical Coll Of Cornell Univ · U19 · FY2021 · AI
SBIR Phase II: A single-cell-interaction platform for accelerating discovery of bispecific antibodies
$1,549,976George G Wu · Amberstone Biosciences, Inc. · · FY2021 · TIP
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
$1,549,397Charles Bix Shoemaker · Tufts University Boston · R01 · FY2025 · AI
Environmental Agents as Modulators of Disease Processes
$1,549,075Thomas A Gasiewicz · University Of Rochester · P30 · FY2009 · ES
Protective Role of Innate Immunity in Autoimmune Disease
$1,547,619Immune Disease Institute, Inc. · P01 · FY2004 · AI
Identifying cell-type specific genetic control of T1D risk variants in TEDDY
$1,547,165Suna Onengut · University Of Virginia · R01 · FY2025 · DK
Methotrexate treatment of Arthritis caused by Chikungunya virus (MARCH): A randomized controlled trial of methotrexate versus placebo in the treatment of chronic arthritis after chikungunya infection
$1,546,361Aileen Chang · George Washington University · U01 · FY2024 · AR
Inhaled GM-CSF Therapy of Autoimmune Pulmonary Alveolar Proteinosis
$1,546,330Sharie Haugabook · National Center For Advancing Translational Sciences · ZIA · FY2019 · TR
Salivary Biomarkers for Sjogren's Syndrome Detection-Definitive Validation
$1,545,921David T Wong · University Of California Los Angeles · U01 · FY2014 · DE
ETIB Clinical Research Core
$1,545,783Ronald Gress · Division Of Basic Sciences - Nci · ZID · FY2020 · CA
Environmental Agents as Modulators of Disease Processes
$1,544,711Thomas A Gasiewicz · University Of Rochester · P30 · FY2008 · ES
Primary Immune Deficiency Treatment Consortium
$1,543,499Morton Cowan · University Of California, San Francisco · U54 · FY2015 · AI
Immune Response Consortium: Integrated In Silico, In Vitro, and In Vivo Studies
$1,543,423Arup K. Chakraborty · Massachusetts Institute Of Technology · P01 · FY2008 · AI
Primary Immune Deficiency Treatment Consortium
$1,543,394Jennifer Maxwell Puck · University Of California, San Francisco · U54 · FY2017 · AI
POTENTIAL FOR ENVIRONMENTAL AND THERAPEUTIC AGENTS TO INDUCE IMMUNOTOXICITY
$1,543,099Kimber White · Virginia Commonwealth University · N01 · FY2010 · ES
Defining New Human Immunodeficiency and Immunodysregulation Disorders
$1,542,930Helen Su · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
Spatiotemporal Health Analytics: Geospatial connections to toxicology
$1,542,384Kyle Messier · National Institute Of Environmental Health Sciences · ZIA · FY2025 · ES
DENDRITIC CELL BIOLOGY AND THERAPY
$1,541,756University Of Pittsburgh At Pittsburgh · P01 · FY2000 · CA
TNF Signaling, Cell Death and Cancer
$1,541,254Zheng-Gang Liu · Division Of Clinical Sciences - Nci · ZIA · FY2023 · CA
A MULTIDISCIPLINARY NMR CENTER FOR BIOMEDICAL RESEARCH
$1,540,140Chien Ho · Carnegie-Mellon University · P41 · FY2008 · EB
Columbia Diabetes Research Center
$1,540,022Domenico Accili · Columbia University Health Sciences · P30 · FY2024 · DK
Integrated Program for Cutaneous Immune-Stromal Interactions in SLE (IPCISS)
$1,540,008Joanne Michelle Kahlenberg · University Of Michigan At Ann Arbor · P01 · FY2025 · AI